Company / Net Income
UroGen Pharma Ltd. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$153.5M
FY2025
5-year range
-$153.5M / -$54.3M
FY2021-FY2025
Trend
-182.4%
vs FY2024
Sector context
#133 of 216
Health Care
What the data says
At -$153M, UroGen Pharma Ltd.'s net income ranks #133 of 216 in the Health Care sector. Net Income has fluctuated over the past 10 years, ranging from -$153M in FY2025 to -$2M in FY2016.
Based on SEC 10-K filings.
-$153M in FY2025.
Declined from -$110M to -$153M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#133 of 216 in Health CareTop 62% of 216This company -$153.5M Sector average $454.3M
▼
-133.8% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 182.4% year-over-year.
- Ranks #133 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$153.5M | -182.4% |
| FY2024 | -$54.3M | +50.5% |
| FY2023 | -$109.8M | +0.9% |
| FY2022 | -$110.8M | +0.0% |
| FY2021 | -$110.8M | -5.4% |
| FY2020 | -$105.1M | -425.7% |
| FY2019 | -$20.0M | +73.6% |
| FY2018 | -$75.7M | -278.3% |
| FY2017 | -$20.0M | -930.4% |
| FY2016 | -$1.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026